Trials / Conditions / B-cell Lymphoma Refractory

B-cell Lymphoma Refractory

21 registered clinical trials studyying B-cell Lymphoma Refractory — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas NCT07319676	National University Hospital, Singapore	Phase 1 / Phase 2
Recruiting	Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia NCT07321301	Daihong Liu	Phase 2
Terminated	Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphom NCT06912529	Universität Münster	Phase 2
Recruiting	CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL NCT06445803	Rong Tao	Phase 1
Recruiting	Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma NCT06552559	Samsung Medical Center	Phase 1 / Phase 2
Not Yet Recruiting	Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lympho NCT05909098	Xiangyang No.1 People's Hospital	Phase 1 / Phase 2
Recruiting	Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lympho NCT05705570	Nelson Hamerschlak	Phase 1
Terminated	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL NCT05360238	Mustang Bio	Phase 1 / Phase 2
Terminated	Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma NCT05318963	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Active Not Recruiting	Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies NCT06220097	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2
Terminated	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744	Mustang Bio	—
Active Not Recruiting	Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autolog NCT04531046	The Lymphoma Academic Research Organisation	Phase 2
Unknown	Induced-T Cell Like NK Cells for B Cell Malignancies NCT04747093	Nanfang Hospital, Southern Medical University	Phase 1 / Phase 2
Completed	CAR T Cell Therapy Related Cardiovascular Outcomes NCT05130489	University College London Hospitals	—
Unknown	A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma NCT04304040	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 1 / Phase 2
Unknown	CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL NCT04303247	Xinqiao Hospital of Chongqing	EARLY_Phase 1
Active Not Recruiting	CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies NCT04214886	Loyola University	Phase 1
Active Not Recruiting	MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) NCT03853616	Miltenyi Biomedicine GmbH	Phase 1
Completed	MB-CART20.1 Lymphoma NCT03664635	Miltenyi Biomedicine GmbH	Phase 1 / Phase 2
Unknown	Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphoma NCT01786018	Azienda Ospedaliera San Giovanni Battista	Phase 2
Completed	Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma NCT01535989	Cristiana Sessa	Phase 1